Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by West Family Investments Inc.

West Family Investments Inc. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,880 shares of the biopharmaceutical company’s stock after selling 503 shares during the period. West Family Investments Inc.’s holdings in Gilead Sciences were worth $881,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GILD. Brookstone Capital Management grew its stake in Gilead Sciences by 10.6% in the 3rd quarter. Brookstone Capital Management now owns 14,547 shares of the biopharmaceutical company’s stock worth $1,141,000 after acquiring an additional 1,390 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in shares of Gilead Sciences by 46.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 202,220 shares of the biopharmaceutical company’s stock valued at $15,154,000 after buying an additional 64,569 shares during the period. Mission Wealth Management LP grew its stake in shares of Gilead Sciences by 3.3% during the 3rd quarter. Mission Wealth Management LP now owns 10,719 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 340 shares during the period. Raymond James & Associates grew its stake in shares of Gilead Sciences by 13.5% during the 3rd quarter. Raymond James & Associates now owns 2,325,094 shares of the biopharmaceutical company’s stock valued at $174,242,000 after buying an additional 276,676 shares during the period. Finally, Stratos Wealth Partners LTD. grew its stake in shares of Gilead Sciences by 7.9% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 107,544 shares of the biopharmaceutical company’s stock valued at $8,059,000 after buying an additional 7,920 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Wells Fargo & Company reduced their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday, April 24th. Finally, StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $0.42 on Thursday, hitting $65.09. The stock had a trading volume of 1,986,627 shares, compared to its average volume of 7,411,257. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The stock has a market cap of $81.04 billion, a price-to-earnings ratio of 180.94, a P/E/G ratio of 1.31 and a beta of 0.22. The company’s 50-day moving average is $70.87 and its two-hundred day moving average is $76.01.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.37 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.73%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.